SCHEMBL2886274

SCHEMBL2886274

CCN1C2CCCC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14418048 0.94 ALDH1A1 (0.36)
SCHEMBL26755729 0.92 GSK3A (0.37)
SCHEMBL2887742 0.88 CHRM2 (0.36)
SCHEMBL2887259 0.88
SCHEMBL8231005 0.87 ALDH1A1 (0.37)
SCHEMBL14417896 0.86 CHRM2 (0.40)
SCHEMBL5731686 0.86 CHRM2 (0.40)
SCHEMBL2887720 0.86 CHRM2 (0.40)
SCHEMBL23475242 0.85 ALDH1A1 (0.36)
SCHEMBL27444779 0.85 ALDH1A1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024011155-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
EP-3897855-B1 KIF18A INHIBITORS AMGEN INC (US) 2023-06-07 EP disclosed
US-10815192-B2 U-47700 immunoassay RANDOX LABORATORIES LTD. (IE) 2020-10-27 US disclosed
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed